Pharma giant Cipla has received the approval from the Food and Drug Administration for its "abbreviated new drug application (ANDA) for anti-HIV/AIDS drug Slamivudine," according to a posting on the FDA site.
The website reported that the tentative approval for ANDA is for an oral solution with strength of 10mg per ml. The new drug belongs to a class of drugs called as nucleoside reverse transcriptase inhibitors. It stops the replication of the HIV virus and hepatitis B virus as well.
Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer